The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Omalizumab facilitates rapid oral desensitization for peanut allergy
Open accessAbstract
Background: Peanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti‐IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions. Objective: We sought to evaluate whether omalizumab facilitated rapid peanut desensitization in highly allergic patients. Methods: Thirty‐seven subjects were randomized to omalizumab (n = 29) or placebo (n = 8). After 12 weeks of treatment, subjects underwent a rapid 1‐day desensitization of up to 250 mg of peanut protein, followed by weekly increases up to 2000 mg. Omalizumab was then discontinued, and subjects continued on 2000 mg of peanut protein. Subjects underwent an open challenge to 4000 mg of peanut protein 12 weeks after stopping study drug. If tolerated, subjects continued on 4000 mg of peanut protein daily. Results: The median peanut dose tolerated on the initial desensitization day was 250 mg for omalizumab‐treated subjects versus 22.5 mg for placebo‐treated subject. Subsequently, 23 (79%) of 29 subjects randomized to omalizumab tolerated 2000 mg of peanut protein 6 weeks after stopping omalizumab versus 1 (12%) of 8 receiving placebo (P < .01). Twenty‐three subjects receiving omalizumab versus 1 subject receiving placebo passed the 4000‐mg food challenge. Overall reaction rates were not significantly lower in omalizumab‐treated versus placebo‐treated subjects (odds ratio, 0.57; P = .15), although omalizumab‐treated subjects were exposed to much higher peanut doses. Conclusion: Omalizumab allows subjects with peanut allergy to be rapidly desensitized over as little as 8 weeks of peanut oral immunotherapy. In the majority of subjects, this desensitization is sustained after omalizumab is discontinued. Additional studies will help clarify which patients would benefit most from this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Randomized trial of peanut consumption in infants at risk for peanut allergy
Du Toit, G., Roberts, G., Sayre, P. H., Bahnson, H. T., Radulovic, S., Santos, A. F., Brough, H. A., Phippard, D., Basting, M., Feeney, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414850 · Cited by 2,237
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
Sicherer, S. H., & Sampson, H. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.020 · Cited by 1,346
Clinical efficacy and immune regulation with peanut oral immunotherapy
Jones, S. M., Pons, L., Roberts, J. L., Scurlock, A. M., Perry, T. T., Kulis, M., Shreffler, W. G., Steele, P., Henry, K. A., Adair, M., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.022 · Cited by 715
Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: A manual
Allan Bock, S., Sampson, H. A., Atkins, F. M., Zeiger, R. S., Lehrer, S., Sachs, M., Bush, R. K., & Metcafe, D. D. (1988) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(88)90135-2 · Cited by 714
Oral Immunotherapy for Treatment of Egg Allergy in Children
Burks, A. W., Jones, S. M., Wood, R. A., Fleischer, D. M., Sicherer, S. H., Lindblad, R. W., Stablein, D., Henning, A. K., Vickery, B. P., Liu, A. H., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200435 · Cited by 700
Effect of Anti-IgE Therapy in Patients with Peanut Allergy
Leung, D. Y. M., Sampson, H. A., Yunginger, J. W., Burks, A. W., Schneider, L. C., Wortel, C. H., Davis, F. M., Hyun, J. D., & Shanahan, W. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022613 · Cited by 691
Self-citationSkripak, J. M., Nash, S. D., Rowley, H., Brereton, N. H., Oh, S., Hamilton, R. G., Matsui, E. C., Burks, A. W., & Wood, R. A. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.030 · Cited by 576
Varshney, P., Jones, S. M., Scurlock, A. M., Perry, T. T., Kemper, A., Steele, P., Hiegel, A., Kamilaris, J., Carlisle, S., Yue, X., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1111 · Cited by 557
Cited by
Sicherer, S. H., & Sampson, H. A. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.003 · Cited by 1,628
EAACI Guidelines on allergen immunotherapy: IgE‐mediated food allergy
Pajno, G. B., Fernandez‐Rivas, M., Arasi, S., Roberts, G., Akdis, C. A., Alvaro‐Lozano, M., Beyer, K., Bindslev‐Jensen, C., Burks, W., Ebisawa, M., et al. (2018) · Allergy · doi:10.1111/all.13319 · Cited by 566
Self-citationThe pathophysiology of anaphylaxis
Reber, L. L., Hernandez, J. D., & Galli, S. J. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.003 · Cited by 507
Renz, H., Allen, K. J., Sicherer, S. H., Sampson, H. A., Lack, G., Beyer, K., & Oettgen, H. C. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.98 · Cited by 377
Tordesillas, L., Berin, M. C., & Sampson, H. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.004 · Cited by 337
Metadata
- Authors
- MacGinnitie, A. J., Rachid, R., Gragg, H., Little, S. V., Lakin, P., Cianferoni, A., Heimall, J., Makhija, M., Robison, R., Chinthrajah, R. S., Lee, J., Lebovidge, J., Dominguez, T., Rooney, C., Lewis, M. O., Koss, J., Burke-Roberts, E., Chin, K., Logvinenko, T., Pongracic, J. A., Umetsu, D. T., Spergel, J., Nadeau, K. C., & Schneider, L. C.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 139
- Issue
- 3
- Pages
- 873-881.e8
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2284588816
- Cited by
- 327
- References
- 47
- FWCI
- 25.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omalizumab facilitates rapid oral desensitization for peanut allergy. https://app.cochat.ai/papers/10.1016/j.jaci.2016.08.010
- The paper
- MacGinnitie, A. J., Rachid, R., Gragg, H., Little, S. V., Lakin, P., Cianferoni, A., Heimall, J., Makhija, M., Robison, R., Chinthrajah, R. S., Lee, J., Lebovidge, J., Dominguez, T., Rooney, C., Lewis, M. O., Koss, J., Burke-Roberts, E., Chin, K., Logvinenko, T., . . . Schneider, L. C. (2017). Omalizumab facilitates rapid oral desensitization for peanut allergy. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2016.08.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.